Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide.

Abstract

A 44-year-old woman with iron deficiency anemia was on a continuous course of intravenous saccharated ferric oxide (SFO). She came to our hospital because of right hip joint pain. She was found to have hypophosphatemia caused by impaired phosphorus resorption and her fibroblast growth factor 23 (FGF-23) levels were elevated. Therefore, she was diagnosed with FGF-23-related osteomalacia due to SFO administration. Discontinuation of the SFO treatment rapidly improved the impaired phosphorus resorption and also normalized the blood levels of phosphorus and FGF-23. During the treatment with SFO, it is important to regularly measure the blood levels of phosphorus in order to prevent the occurrence of osteomalacia.

• Authors: Sunao Yamamoto, Yosuke Okada, Hiroko Mori, Seiji Fukumoto, Yoshiya Tanaka
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 51 Issue 17 Pg. 2375-8 ( 2012) ISSN: 1349-7235 [Electronic] Japan
• PMID: 22975552 (Publication Type: Case Reports, Journal Article)

Chemical References

• FGF23 protein, human
• Ferric Compounds
• Hematinics
• Phosphorus
• Fibroblast Growth Factors
• Fibroblast Growth Factor-23
• Ferric Oxide, Saccharated
• Glucaric Acid

Topics

• Absorptiometry, Photon
• Adult
• Anemia, Iron-Deficiency (blood, drug therapy)
• Dose-Response Relationship, Drug
• Female
• Ferric Compounds (adverse effects, therapeutic use)
• Ferric Oxide, Saccharated
• Fibroblast Growth Factor-23
• Fibroblast Growth Factors (blood)
• Glucaric Acid (adverse effects, therapeutic use)
• Hematinics (adverse effects, therapeutic use)
• Humans
• Osteomalacia (chemically induced, diagnosis, metabolism)
• Phosphorus (blood)
• Time Factors
• Treatment Outcome
• Withholding Treatment